Life Extension Magazine December 2007
Carnitine and Thyroid Disease
By Julius G. Goepp, MD
Carnitine—The Latest Findings
As noted, virtually all of the modern work on carnitine in hyperthyroidism has come from the Italian research group led by Dr. Benvenga. Though their work is dramatic and compelling, scientists often have legitimate concerns about findings that haven’t been replicated or supported by additional researchers. In just the past two years, several new studies have come from completely different laboratories, each examining separate issues that together provide strong assurance of carnitine’s value for individuals who suffer from thyroid disease.
Specifically interested in the muscle weakness that accompanies both hyper- and hypothyroid conditions, Dr. Christopher Sinclair and colleagues at Brown Medical School in Rhode Island performed their own set of studies, which were published in 2005.6 The researchers obtained skeletal muscle samples from both hyper- and hypothyroid patients, as well as from a group of normal controls. Samples from patients with thyroid disease were also repeated after a course of appropriate traditional treatment. When they measured muscle carnitine content in the samples, the researchers found a significant reduction in hyperthyroid patients, with a return to normal levels as the condition improved under treatment. They found smaller, less significant decreases in muscle carnitine content in the hypothyroid group as well, which also improved with treatment. Dr. Sinclair and his colleagues, like their Italian counterparts, recognized that the decreased availability of carnitine in muscles means that “there will be less energy (in the form of long-chain fatty acids) transported into the mitochondria” and further point out that “this might lead to diminished fatty acid oxidation in skeletal muscle and, consequently, lead to weakness.”
A completely separate line of evidence about the importance of carnitine in protecting muscle integrity comes from the world of cancer treatment. In a 2005 study of a new chemotherapy drug called aplidine, French scientists included carnitine supplements to assure the safety of the new drug.29 Aplidine is a chemical derived from marine creatures called tunicates, or sea-squirts. It has potent anticancer effects but its dose is limited by myotoxicity, or muscle damage and weakness. When 3 of their 14 patients experienced toxicity from aplidine that limited their ability to increase the dose, the researchers simply provided oral carnitine. Carnitine was able to reverse the muscle toxicity, and patients who continued on the supplement were able to increase their chemotherapy doses by 40%. The researchers intend to conduct further studies of carnitine as a muscle protectant in future research.
There is no doubt that carnitine, a humble molecule used in the basic economics of cellular energy, holds the key to preventing and even reversing muscle damage and weakness from a variety of causes, including hyperthyroidism. Clinical trials investigating L-carnitine in thyroid conditions have utilized doses ranging from 2,000 to 4,000 mg daily. While these studies have focused on L-carnitine, advanced carnitine formulations such as acetyl-L-carnitine, acetyl-L-carnitine arginate, and propionyl-L-carnitine may also offer promise for individuals who suffer from thyroid conditions. More research is needed to determine which carnitine formulations are most beneficial for modulating the adverse effects of hyperthyroidism.
Carnitine is safe and has no known side effects, and is in widespread use for a number of indications, including the muscle fatigue that can result from strenuous exercise. The story of carnitine’s rise from obscurity is truly one of modern medical science’s most dramatic and compelling tales of success.
If you have any questions on the scientific content of this article, please call a Life Extension Health Advisor at 1-800-226-2370.
1. Laurberg P, Andersen S, Bulow P, I, Carle A. Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment. Drugs Aging. 2005;22(1):23-38.
2. Jayakumar RV. Hypothyroidism. J Indian Med Assoc. 2006 Oct;104(10):557-60, 562.
3. Heitman B, Irizarry A. Hypothyroidism: common complaints, perplexing diagnosis. Nurse Pract. 1995 Mar;20(3):54-60.
4. Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases. Curr Opin Rheumatol. 2007 Jan;19(1):44-8.
5. Maji D. Hyperthyroidism. J Indian Med Assoc. 2006 Oct;104(10):563-7.
6. Sinclair C, Gilchrist JM, Hennessey JV, Kandula M. Muscle carnitine in hypo- and hyperthyroidism. Muscle Nerve. 2005 Sep;32(3):357-9.
7. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am. 2006 Dec;35(4):663-86, vii.
8. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993 Jun;22(2):263-77.
9. Olson BR, Klein I, Benner R, et al. Hyperthyroid myopathy and the response to treatment. Thyroid. 1991;1(2):137-41.
10. Strack E, Woratz G, Rotzsch W. Effects of carnitine in hyperfunction of the thyroid gland. Endokrinologie. 1959 Sep;38:218-25.
11. Strack E, Bloesche H, Bemm H, Rotzsch W. Use of L-carnitine in hyperfunction of the thyroid gland. Dtsch Z Verdau Stoffwechselkr. 1962 Apr;21:253-9.
12. Willgerodt H, Rotzsch W, Strack E. Effect of carnitine of the accumulation of iodine in the thyroid gland. Dtsch Z Verdau Stoffwechselkr. 1965 Aug;25(3):127-35.
13. Emmrich R. New methods for the diagnosis and therapy of hyperthyroidism. Munch Med Wochenschr. 1967 Oct 27;109(43):2217-21.
14. Maebashi M, Kawamura N, Sato M, Imamura A, Yoshinaga K. Urinary excretion of carnitine in patients with hyperthyroidism and hypothyroidism: augmentation by thyroid hormone. Metabolism. 1977 Apr;26(4):351-6.
15. Fosslien E. Review: Mitochondrial medicine—cardiomyopathy caused by defective oxidative phosphorylation. Ann Clin Lab Sci. 2003;33(4):371-95.
16. Jacob C, Belleville F. L-carnitine: metabolism, functions and value in pathology. Pathol Biol (Paris). 1992 Nov;40(9):910-9.
17. Sestoft L. Metabolic aspects of the calorigenic effect of thyroid hormone in mammals. Clin Endocrinol (Oxf). 1980 Nov;13(5):489-506.
18. Turakulov I, Saatov TS, Rakhimdzhanova MT, Ismailkhodzhaeva G. Oxidation of palmityl carnitine in mitochondria of rat heart and liver tissue under conditions of thyroid pathology. Vopr Med Khim. 1981 Mar;27(2):197-200.
19. Suzuki M, Tokuyama K, Yamane A. Carnitine metabolism in thyroid hormone treated rats and mice. J Nutr Sci Vitaminol (Tokyo). 1983 Aug;29(4):413-28.
20. Galland S, Georges B, Le Borgne F, Conductier G, Dias JV, Demarquoy J. Thyroid hormone controls carnitine status through modifications of gamma-butyrobetaine hydroxylase activity and gene expression. Cell Mol Life Sci. 2002 Mar;59(3):540-5.
21. Benvenga S, Amato A, Calvani M, Trimarchi F. Effects of carnitine on thyroid hormone action. Ann NY Acad Sci. 2004 Nov;1033:158-67.
22. Muller MJ, Koster H, Seitz HJ. Effect of thyroid state on ketogenic capacity of the isolated perfused liver of starved rats. Biochim Biophys Acta. 1981 Dec 23;666(3):475-81.
23. DeFelice SL, Gilgore SG. The antagonistic effect of carnitine in hyperthyroidism. Preliminary report. J New Drugs. 1966 Nov;6(6):351-3.
24. Gilgore SG, DeFelice SL. Evaluation of carnitine—an antagonist of thyroid hormone. Clinical pharmacology report. J New Drugs. 1966 Nov;6(6):349-50.
25. Benvenga S, Lakshmanan M, Trimarchi F. Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake. Thyroid. 2000 Dec;10(12):1043-50.
26. Benvenga S, Ruggeri RM, Russo A, et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2001 Aug;86(8):3579-94.
27. Migneco A, Ojetti V, Testa A, De LA, Gentiloni SN. Management of thyrotoxic crisis. Eur Rev Med Pharmacol Sci. 2005 Jan;9(1):69-74.
28. Benvenga S, Lapa D, Cannavo S, Trimarchi F. Successive thyroid storms treated with L-carnitine and low doses of methimazole. Am J Med. 2003 Oct 1;115(5):417-8.
29. Faivre S, Chieze S, Delbaldo C, et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol. 2005 Nov 1;23(31):7871-80.